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atherosclerosis. However, data on the impact of
hypertension in patients with ST-segment elevation
myocardial infarction (STEMI) are inconsistent, and mainly
related to studies performed in the thrombolytic era, with
very few data on patients undergoing primary angioplasty.
The aim of the current study was to evaluate the impact
of hypertension on scintigraphic infarct size in STEMI
patients undergoing primary percutaneous coronary
intervention (PCI).
Method: Our population is represented by 830 STEMI
patients undergoing primary PCI. Infarct size was evaluated
at 30 days by technetium-99m-sestamibi.
Results: Hypertension was associated with more advanced
age (P< 0.001), a larger prevalence of diabetes
(P¼0.001), female sex (P<0.001), but lower prevalence
of smoking (P<0.001) and anterior infarction (P¼0.042).
No difference was observed in ischemia time, cardiogenic
shock at presentation, in preprocedural thrombolysis in
myocardial infarction (TIMI) flow, and collateral circulation.
Hypertension did not affect the rate of postprocedural TIMI
3 flow. Hypertension did not affect infarct size [12.5%
(4.1–23.8%) vs. 12.8% (4.3–24.7%), P¼0.38]. Similar
results were observed in subanalyses in major high-risk
subgroups. No impact of hypertension on infarct size was
confirmed when the analysis was conducted according to
the percentage of patients with infarct size above the
median [adjusted odds ratio (95% CI)¼0.97 (0.72–1.33),
P¼0.92].
Conclusion: This study shows that among STEMI patients,
undergoing primary PCI hypertension does not affect
scintigraphic infarct size.
Keywords: hypertension, infarct size, percutaneous
coronary intervention, primary angioplasty, ST elevation
myocardial infarction
Abbreviations: ACS, acute coronary syndrome; CAD,
coronary artery disease; LV, left ventricle; SPECT, single-
photon emission computer tomography; STEMI, ST-
segment elevation acute myocardial infarction; TIMI,
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Journal of HypertensionINTRODUCTIONA
vailability of pharmacologic and mechanical reper-
fusion therapies has significantly reduced cardiac
mortality among ST-segment elevation acute myo-
cardial infarction (STEMI) patients [1–6]. However, even
though primary angioplasty has been shown to provide
larger benefits as compared with thrombolysis, a subopti-
mal myocardial reperfusion is observed in a still relevant
proportion of patients, despite optimal epicardial recanal-
ization [7–9]. Hypertension is an established risk factor for
atherosclerosis [10]. However, data on the prognostic
impact of hypertension in patients with STEMI are so far
inconsistent, mainly related to studies performed in the
thrombolytic era [11–15]. In fact, although elevated levels of
heart failure, stroke, cranial hemorrhage, and mortality risk
have been shown in patients with antecedent hypertension
receiving thrombolytic therapy [10–16], still controversial is
the prognostic role of hypertension in terms of survival after
primary angioplasty [17–20]. In particular, few data focused
on the impact of hypertension on infarct size. Therefore, the
aim of the current study was to evaluate the impact of
hypertension on scintigraphic infarct size in STEMI patients
undergoing primary angioplasty.
MATERIALS ANDMETHODS
Our initial population included 894 patients with STEMI
treated by primary angioplasty scheduled to undergo evalu-
ation of the infarct size at 30 days after the intervention [21].
A total of 64 patients [16 women (8.7%) and 48 men (7.4%)]
were excluded because of death (n¼ 16), reinfarction
(n¼ 7), or target vessel revascularization (n¼ 11) within
30 days from revascularization, or refusal to undergoorized reproduction of this article is prohibited.
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De Luca et al.scintigraphy (n¼ 30). Therefore, our final population was
830 patients. All patients were admitted within 12 h from
symptom onset, and received at the time of diagnosis
aspirin (500mg intravenously), heparin (60 IU/kg intra-
venously), b-blockers, and nitroglycerine intravenously
if not contraindicated, but the decision to provide glyco-
protein IIb-IIIa inhibitors was left to the discretion
of the operator at the time of intervention. All patients
were on dual oral antiplatelet therapy (aspirin and clopi-
dogrel or ticlopidine) for at least 4 weeks after stent
implantation. All demographic, clinical, procedural, and
in-hospital and follow-up data were collected in a data-
base. Patients were categorized as having antecedent
hypertension, if this diagnosis was known by the patient
to have been made by the family physician or after special-
ist referral and/or the admission note indicated a history
of hypertension.
Coronary angiography and mechanical
revascularization
Selective coronary angiography was performed in multiple
projections before mechanical reperfusion. Immediately
after diagnostic angiography, percutaneous coronary inter-
vention (PCI) with stenting of the infarct-related vessel was
performed using standard material. Successful primary PCI
was defined as thrombolysis in myocardial infarction (TIMI)
grade 3 coronary flow in the treated vessel with a residual
stenosis less than 20%.
Infarct size assessment
As previously described [21], gated single-photon emission
computed tomography (SPECT) acquisition began 60min
after technetium-99m-sestamibi injection (740MBq), using
a double-head gamma-camera equipped with high-resol-
ution collimators, 1808 rotation arc, 32 projections, 60 s/
projection, 8 frames/heart cycle, and 64 64 matrices. The
studies were reconstructed using filtered back-projection
without attenuation or scatter correction and realigned
along the heart axis. Perfusion defects were quantified asCopyright © Lippincott Williams & Wilkins. Unaut
TABLE 1. Demographic and clinical characteristics according to histor
Variable Hypertension (n¼362)
Age 67 (59–75)
Age >75 years (%) 26.8
Female sex (%) 28.7
Smoking (%) 37.3
Dyslipidemia (%) 35.1
Diabetes (%) 18.2
Previous MI (%) 4.7
Previous CABG (%) 0.6
Previous PTCA (%) 4.2
Ischemia time (min) 204 (145–272)
Ischemia time >3h (%) 59.9
Anterior MI (%) 36.2
aCardiogenic shock (%) 4.1
aSBP (mmHg) 125 (110–140)
aDBP (mmHg) 80 (70–85)
aHeart rate (bpm) 72 (60–81)
CABG, coronary artery bypass grafting; MI, myocardial infarction; PTCA, percutaneous translum
aAt hospital admission.
2434 www.jhypertension.compercentage involvement of left ventricular wall, with the
defect threshold set at 60% of peak uptake [22].
Statistical analysis
Statistical analysis was performed using the SPSS, version
15.0, statistical package (SPSS, Chicago, Illinois, USA).
Continuous data are expressed as the median (25th–75th
percentiles) and categorical data as percentages. The
analysis of variance test or Mann–Whitney U-test was
appropriately used for continuous variables, according to
the normality of distribution, as evaluated by the Shapiro–
Wilk test. The x2 test or Fisher’s exact test was used for
categorical variables. Multiple logistic regression analysis
was used to evaluate the effect of hypertension on infarct
size (as above the median) after adjustment for significant
(P<0.05) confounding baseline characteristics. Interaction
between hypertension and other major variables (age, sex,
diabetes, infarct location, ischemia time) on infarct size was
evaluated by analyzing the categorical by continuous var-
iable interactions, as previously described [23].RESULTS
Patients’ characteristics are shown in Tables 1 and 2. Hy-
pertension was associated with more advanced age
(P< 0.001), a larger prevalence of diabetes (P¼ 0.001),
female sex (P<0.001), but lower prevalence of smoking
(P<0.001) and anterior infarction (P¼ 0.042). As expected,
hypertension was associated with higher SBP (P¼ 0.045)
and DBP (P¼ 0.011) at admission, without any difference in
heart rate. No difference was observed in ischemia time,
cardiogenic shock at presentation, in preprocedural TIMI
flow, and collateral circulation. Hypertension did not affect
the rate of postprocedural TIMI 3 flow.
As shown in Figure 1, hypertension did not affect infarct
size [12.2 (4.1–23.8) vs. 12.8 (4.3–24.7), P¼ 0.38]. Similar
results were observed in subanalyses according to
advanced age [<65 years: 12.5% (4.55–21.7%) vs. 12.8%
(5–24.4%), P¼ 0.25; >65 years: 12.1% (3.4–24.8%) vs.horized reproduction of this article is prohibited.
y of hypertension
Control (n¼468) P value
61 (53–69) <0.001
15 <0.001
14.7 <0.001
56.8 <0.001
33.1 0.55
10.5 0.001
3.6 0.44
1.1 0.42
3.2 0.52
200 (149–275) 0.42
58.8 0.75
43.2 0.042
3.8 0.83
120 (105–140) 0.045
70 (65–80) 0.011
74 (65–81) 0.35
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TABLE 2. Angiographic and procedural characteristics according
to history of hypertension
Variable
Hypertension
(n¼362)
Control
(n¼468)
P
value
Collateral circulation 0.31
RENTROP 0 (%) 92.3 87
RENTROP 1 (%) 5.4 8.5
RENTROP 2 (%) 2.4 3.6
RENTROP 3 (%) 0 0.8
Preprocedural TIMI flow 0.43
TIMI 0–1 (%) 80.6 81.8
TIMI 2 (%) 10 11.2
TIMI 3 (% 9.4 7.1 0.22
Infarct-related artery 0.21
RCA (%) 48.6 42.7
Cx (%) 15.2 13.7
Graft (%) 0 0.2
LAD (%) 36.2 43.2
LM (%) 0 0.2
Multivessel disease (%) 43.9 39.6 0.22
Number of lesions 0.28
1 (%) 72.9 78.4
2 (%) 21.3 16.5
3 (%) 5.8 5.2
Abciximab (%) 88.9 91.4 0.22
Stenting (%) 100 98 0.95
IABP (%) 3.6 3.8 0.85
Postprocedural TIMI 3 flow (%) 93.3 91.4 0.33
Cx, circumflex; IABP, intraaortic balloon pump; LAD, left anterior descending; LM, left
main; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
Hypertension and infarct size13.3% (4–25.1%), P¼ 0.78; P interaction¼ 0.74], sex [female
sex: 5.25% (0–17.8%) vs. 8.6% (0–21.5%), P¼ 0.23; male
sex: 14% (6.3–25.1%) vs. 13.9% (5.5–25.9%), P¼ 0.65; P
interaction¼ 0.38], diabetes [diabetic patients: 10.3% (3.3–
25%) vs. 10% (4–23.6%), P¼ 0.96; no diabetes: 12.5% (4.5–
23.8%) vs. 13.7% (4.6–24.8%), P¼ 0.28; P inter-
action¼ 0.52], ischemia time [<3 h: 9.6% (4.5–17.8%) vs.
11.6% (4–22.1%), P¼ 0.13;>3 h: 15.1% (4–25.2%) vs. 15%Copyright © Lippincott Williams & Wilkins. Unauth
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FIGURE 1 Bar graphs show the impact of hypertension on infarct size. Data are
presented as median (25th–75th percentile).
Journal of Hypertension(5.1–26.5%), P¼ 0.89; P interaction¼ 0.19], and infarct
location [anterior STEMI: 15.5% (6.1–29.1%) vs. 16%
(5.6–29.7%), P¼ 0.97; nonanterior STEMI: 10.7% (2–21%)
vs. 11.8% (3.9–21.5%), P¼ 0.39; P interaction¼ 0.64]. No
relationship was observed between SBP (r¼ 0.06,
P¼ 0.25), DBP (r¼ 0.04, P¼ 0.42) at admission with
infarct size.
Similar results were observed when the analysis was
conducted according to the percentage of patients with
infarct size above the median (Figure 2), which were
confirmed after correction for baseline characteristics, such
as age, smoking, diabetes, sex, anterior MI, and blood
pressure at admission [odds ratio, OR (95% confidence
interval, CI)¼ 0.97 (0.72–1.33), P¼ 0.92].
DISCUSSION
This is one of the largest studies so far conducted showing
no impact of hypertension on scintigraphic infarct size in
STEMI patients undergoing primary PCI.
Hypertension currently represents a major risk factor for
atherosclerosis and heart failure. However, still controver-
sial is its prognostic impact after STEMI. Several mechan-
isms may contribute to explain a potential impact of
hypertension on outcome after STEMI. Patients with hy-
pertension may have higher risk profile, such as more
advanced age, higher rates of diabetes, and more extensive
coronary artery disease (CAD; 10–20). However, higher
diastolic pressure may improve collateral circulation and
coronary perfusion and may, therefore, positively impact
on the success of reperfusion and infarct size. In addition, a
thicker left ventricle may positively affect left ventricular
remodeling, with a reduction in left ventricular dilatation
[19].
Several reports have investigated the prognostic impact
of hypertension on outcome among patients treated with
thrombolysis. Rabkin et al. [11] showed a negative impact of
hypertension on short-term and long-term outcome in
STEMI patients. In the Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto (GISSI-2) study, in-hospital and
6-month mortality in hypertensive STEMI patients were
significantly higher compared with normotensive indivi-
duals [12], as was the rate of left ventricular failure, recurrent
angina, and recurrent MI. Aylward et al. [13], evaluating allorized reproduction of this article is prohibited.
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FIGURE 2 Bar graphs show the impact of hypertension on infarct size (as percent-
age of patients above the median).
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De Luca et al.patients participating in the GUSTO-1 study, observed that
the risk of an early death was higher in patients with
elevated SBP. In a study by Majahalme et al. [14], in-hospital
and 6-month mortality in hypertensive and normotensive
acute coronary syndrome (ACS) patients were similar,
whereas the rate of recurrent angina, paroxysmal atrial
fibrillation, and acute renal failure was higher among
patients with hypertension.
While the negative prognostic impact of hypertension
after thrombolysis in patients STEMI, has been clearly
demonstrated, and mainly due to higher rates of heart
failure, stroke, cranial hemorrhage, and mortality [10–16],
only a few studies [17–20] have assessed the impact of
hypertension on outcome after primary angioplasty, which
currently represents the best reperfusion strategy.
Abrignani et al. [18] observed that hypertensive patients
with first acute myocardial infarction (AMI) have a better
in-hospital outcome than age-matched and sex-matched
normotensive individuals. On the contrary, in a recent
paper by Rembek et al. [17] performed in 366 STEMI
patients submitted to mechanical revascularization, no
difference was observed in in-hospital mortality between
hypertensive and normotensive patients. Parodi et al. [19]
analyzed the impact of hypertension on 6-month left ven-
tricular remodeling and 5-year outcome in 953 STEMI
patients undergoing primary angioplasty, showing no
impact on remodeling and mortality. However, hyperten-
sion was associated with higher risk of heart failure due to
diastolic dysfunction.
In a recent study, Lazzeri et al. [20] in a population of 560
STEMI patients without known diabetes, showed at a
median follow-up of 32 months no impact of hypertension
on mortality.
This is the first study investigating the impact of hyper-
tension on infarct size as evaluated by scintigraphic tech-
nique. In accordance with previous studies, we found that
patients with hypertension have a higher risk profile, being
older, with higher prevalence of female sex, diabetes, but
lower prevalence of smoking and anterior MI. No differ-
ence was observed in preprocedural TIMI flow, extension
of CAD, and coronary collaterals. In particular, no differ-
ence was observed in postprocedural TIMI 3 flow. Hyper-
tension was not associated with larger infarct size, even
after correction for baseline confounding factors and in
major high-risk subgroups of patients.
Study limitations
We assessed infarct size 1 month after the index infarction
instead of at hospital discharge, as in the majority of
previously published studies. On the other hand, this
circumstance should be more effective in preventing inter-
ference of myocardial stunning with the extent of perfusion
defects [24]. Coronary angiographic control before gated
SPECT to allow the exclusion of infarct-related vessel
restenosis was not routinely performed. Caution should
be exercised in extending our conclusions to all STEMI
populations. In fact, our patients were part of randomized
trials that had scintigraphic infarct size as an endpoint.
Therefore, patients included in our study were, by defi-
nition, survivors at 30 days, with a subsequent potential
selection bias. Uncontrolled hypertension during theCopyright © Lippincott Williams & Wilkins. Unaut
2436 www.jhypertension.comcourse of infarction, as much as at the time of scintigraphy,
might have influenced infarct size evaluation. Unfortu-
nately, with the only exception of blood pressure values
at admission, which were not associated with infarct size,
detailed data on blood pressure control were not available.
Furthermore, the definition of hypertension was based on
clinical history at admission. While this may certainly
represent a limitation, it must be recognized that the use
of blood pressure at admission may be misleading, because
it may be influenced by the infarction and the associated
psychological stress, and therefore may not certainly be a
marker of hypertension. Finally, data on weight/BMI were
not collected and, therefore, unavailable.
In conclusion, this study showed that among STEMI
patients, undergoing primary angioplasty hypertension
does not affect scintigraphic infarct size.
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